Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen - Test2 - elhamkhani - TriplyDB

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

http://www.wikidata.org/entity/Q21092375

about

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells The combined status of ATM and p53 link tumor development with therapeutic response Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1 IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland The rebel angel: mutant p53 as the driving oncogene in breast cancer.p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.Should we abandon the t-test in the analysis of gene expression microarray data: a comparison of variance modeling strategies Clinical outcomes and correlates of TP53 mutations and cancer.Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods.TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.Breast cancer genomes--form and function TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.The p53 inducing drug dosage may determine quiescence or senescence.Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.TP53 status and response to treatment in breast cancers Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo.Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy A refined molecular taxonomy of breast cancer.Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer.TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Clinical next generation sequencing to identify actionable aberrations in a phase I program.Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.

P2860

Q21563402-94404FD4-2967-484E-B37D-D32604515411 Q24629061-AC639679-C1FC-4AF9-8249-D9375716357C Q24652535-0DDA07E4-09D5-45AC-B1CD-B7EA18232C47 Q24657893-3B057A43-484D-4693-B4EF-BDBA96FB5DF2 Q24669531-00CF6A6D-CAD3-4365-8792-60B15F975DF2 Q27686765-6DA25ECA-76A4-468F-BD12-5C6F440C3DFC Q27851827-CF99313E-4310-48DA-B8C0-084388EF696A Q28271428-4D57D688-93A8-47AE-9794-79F1F011A3B1 Q28372484-C3358B56-C363-4204-9835-3DE7BC7C7BD9 Q28468360-03F3C524-093C-4D4E-9415-1061BB603480 Q28473504-1F32D951-0EE0-4743-8BB6-51FCD1645893 Q30366115-79FEBA7C-9E75-42EE-BDF8-9A707CF547DB Q30497664-AC75D4AF-A32A-4693-AC6B-5499F505E134 Q30978083-31D774BB-A04C-47F8-8502-87362C02F014 Q33299319-1F1D0518-B4D6-4340-9741-B2E7F4F13E17 Q33691313-37B02C75-7F9C-456F-ABFB-7FA84940164E Q33693838-32EFA12C-3D05-4076-919A-B6F5AC7B7462 Q33827045-4F5909AE-D21F-4CBC-AB67-09B0718C8C8D Q33860865-E3238239-80B0-45CE-BA7B-5BFEA403F336 Q34130168-F6AFDFEC-530A-4CD4-8ED2-69A8A8C839BB Q34207688-699BED2F-D618-45AF-81C0-15D47BA4B561 Q34234217-23DD1F88-1721-403F-9082-B84FCF8F8A58 Q34328227-00A88D34-44DA-46DB-8FF1-D559F3FA2B17 Q34424866-89AB8514-6DE9-455E-B614-C092ABBAC828 Q34428974-14BE511B-E037-41BB-8E9C-085E0508950B Q34433737-636FE999-9018-4AB8-9CB5-F303B1F46BCC Q34961997-9FFD933B-DAA1-4F96-AAD6-292CADF656A5 Q35029530-0D5D56C4-FE77-4AEF-BB8C-E2F10BF85B9C Q35043933-A4AC4DDC-6F7A-4633-9BFB-E8FC49F599B2 Q35140413-F88F7D48-1BFB-4D11-8936-1247EC6DEC55 Q35349417-DE340883-5B74-4B53-8A59-F710CC21499A Q35583968-02FC9474-7634-4D0D-B5F0-9DDDF4EE16BB Q35740145-EE4F68D7-D7DF-453B-9129-1E92EA140F69 Q35838290-473A3501-E067-4375-8B7E-2ECA401A1CCA Q36092750-AD1D6642-C5AF-47E6-826F-B5198AC5CD27 Q36148592-3AD0DB65-36A8-41DB-9BD1-E2A98A08B56E Q36245341-CEC3CBC7-1A5B-49F2-B18B-10DF8B24E399 Q36299589-8750AA69-99F0-485A-BD65-63DCEF9FC704 Q36385696-5EDF091A-359F-451D-B154-2D98F1E3B042 Q37287418-E8BAD543-F8DE-4EFA-A8BF-5E2E17E4F444

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

http://www.wikidata.org/entity/Q21092375

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@ast

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en-gb

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@nl

type

label

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@ast

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en-gb

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@nl

altLabel

Exquisite Sensitivity of TP53 ...... bicin−Cyclophosphamide Regimen

@en

prefLabel

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@ast

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en-gb

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@nl

P1433

Q21092375-C83419DB-8F25-4C8F-BE87-2451D70F55AA

P1476

Q21092375-6938448B-EA6A-40A6-9A06-073375FF2AA9

P2093

Q21092375-05FD2FAF-BAF2-4D31-9AB8-6E803E159C96

Q21092375-1D427180-92FF-4088-B71F-6DCDCC170CF6

Q21092375-24E223F9-C612-4AC8-B504-5DAECD856808

Q21092375-357EF737-8FF3-42D2-83FD-3017B33ADB83

Q21092375-44165299-5B5E-4B01-B2E7-E1AA7E6488B5

Q21092375-688201AD-F2A2-4775-994B-505A68676FAF

Q21092375-6A2954C4-E87A-4202-AA9F-8949F4FF1CBF

Q21092375-8B2A6E7D-7F44-4798-99B7-282C905D8C2F

Q21092375-99F7EAD9-5C85-40A3-9674-50EF53A4D2C0

Q21092375-A70C8657-75C8-4DEA-BC60-8B815FDCF6C7

P2860

Q21092375-0B59E904-FF29-44D5-AB62-6C34D1DBEA51

Q21092375-0F6BF933-DB32-407B-A76F-2DD3A2182098

Q21092375-0FC98444-571E-45E2-9EF4-8907F6E3E427

Q21092375-1AABA050-F060-4D87-9E09-CE45891AE0EE

Q21092375-29D4E0DB-15EF-41B1-8894-D51162F6335F

Q21092375-2D67BF81-C56F-461E-95FF-4BE791077BCE

Q21092375-2F061BF2-2BB0-4DAB-80A9-6C9F65DDCD16

Q21092375-2F7D50C7-F4E6-42AB-9657-667213FD69C9

Q21092375-37AADF00-9B43-431D-851D-513688D38AA0

Q21092375-3970CDA2-764E-40CA-A8E0-F0DB0412DCDF

P304

Q21092375-10462B1E-17C3-4A95-B10A-578EF6385C35

P31

Q21092375-0D20BCA1-D4BE-47A4-8488-F6E183544261

P3181

Q21092375-475CB460-CF62-45E3-9A16-83FAE44DDE95

P356

Q21092375-FBB20BC5-634B-4BEA-A929-7ED286C749D3

P407

Q21092375-E1FE4B55-F2BB-4888-B0C8-C70CB04E858E

P433

Q21092375-F0AE21CA-A5C7-4D2B-AF3D-A05E116DED43

P478

Q21092375-DCAA7ACE-B4BC-488E-AB94-F2187EE1A0DE

P50

Q21092375-01129DFB-6B36-4323-83B9-CAB96EAF5BAD

Q21092375-24A829A5-7E51-4D4C-B168-4CC9C238CA01

Q21092375-355154A3-EBCC-4989-90DD-FB0025292386

P577

Q21092375-1B3D35CD-8070-4C45-9B6B-6D65BAEEE53F

P5875

Q21092375-992E7668-1EC4-4B3B-BC78-5B0DD06EEFF9

P698

Q21092375-823BC4B6-7642-4181-BA34-B1A85FEEC698

P921

Q21092375-5383D619-978E-4DA4-AB73-D09132C1D385

P932

Q21092375-8E7C7DE7-AB3F-4043-BE54-DF82D03146D4

P3181

P356

JOURNAL.PMED.0040090

P1433

P1476

Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen

@en

P2093

Anne Janin

http://www.w3.org/2001/XMLSchema#string

Anne de Roquancourt

http://www.w3.org/2001/XMLSchema#string

David S Rickman

http://www.w3.org/2001/XMLSchema#string

Elisabeth Turpin

http://www.w3.org/2001/XMLSchema#string

Hany Soliman

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Misset

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Feugeas

http://www.w3.org/2001/XMLSchema#string

Louis-François Plassa

http://www.w3.org/2001/XMLSchema#string

Marc Espié

http://www.w3.org/2001/XMLSchema#string

Mariana Varna

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Identification of human brain tumour initiating cells

Molecular portraits of human breast tumours

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

p53 and cancer therapy: a double-edged sword.

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

P304

e90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4880182

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0040090

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Aurélien de Reyniès

Jacqueline Lehmann-Che

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6418188

http://www.w3.org/2001/XMLSchema#string

P698

17388661

http://www.w3.org/2001/XMLSchema#string

P921

P932

1831731

http://www.w3.org/2001/XMLSchema#string